Diuretics Are Preferred Over Angiotensin II-Converting Enzyme Inhibitors For Initial Therapy of Uncomplicated Hypertension

American Journal of Kidney Diseases

Volumn 50, Issue 2, 2007, Pages 188-196

  Grimm, Richard ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; GLUCOSE; HYDROCHLOROTHIAZIDE; LISINOPRIL; PLACEBO; RAMIPRIL; VALSARTAN;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUSTRY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PEPTIDYL-DIPEPTIDASE A;

EID: 34447631335     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.06.007     Document Type: Article

References (39)

1. Novello R.C., and Sprague J.M. Benzothiadiazine dioxides as novel diuretics. J Am Chem Soc 79 (1957) 2028
2. No authors listed. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202 (1967) 1028-1034
3. Veterans Cooperative Group. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213 (1970) 1143-1152
4. Ondetti M.A., Rubin B., and Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196 (1977) 441-444
5. Stafford R.S., Monti V., Furberg C.D., and Ma J. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension 48 (2006) 213-218
6. No authors listed. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. JAMA 242 (1979) 2572-2577
7. Conway J., and Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 21 (1960) 21-27
8. Zhu Z., Zhu S., Liu D., Cao T., Wang L., and Tepel M. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 45 (2005) 233-239
9. No authors listed. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991) 3255-3264
10. Stamler J., Prineas R.J., Neaton J.D., et al. Background and design of the new U.S. trial on diet and drug treatment of "mild" hypertension (TOMHS). Am J Cardiol 59 (1987) 51G-60G
11. ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
12. Elmer P.J., Grimm Jr. R., Laing B., et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med 24 (1995) 378-388
13. Neaton J.D., Grimm Jr. R.H., Prineas R.J., et al., Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 270 (1993) 713-724
14. Neaton J.D., Wentworth D., and Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med 152 (1992) 56-64
15. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283 (2000) 1967-1975
16. Staessen J.A., Gasowski J., Wang J.G., et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355 (2000) 865-872
17. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
18. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
19. Staessen J.A., Wang J.G., and Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358 (2001) 1305-1315
20. Smith W.M. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res 40 (1977) I98-I105
21. No authors listed. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242 (1979) 2562-2571
22. Grimm Jr. R.H., Cohen J.D., Smith W.M., Falvo-Gerard L., and Neaton J.D. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. Arch Intern Med 145 (1985) 1191-1199
23. No authors listed. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 248 (1982) 1465-1477
24. Wing L.M., Reid C.M., Ryan P., et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
25. No authors listed. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 82 (1990) 1616-1628
26. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358
27. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 936-946
28. Casas J.P., Chua W., Loukogeorgakis S., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
29. Whelton P.K., Barzilay J., Cushman W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 1401-1409
30. Wright Jr. J.T., Agodoa L., Contreras G., et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 162 (2002) 1636-1643
31. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
32. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
33. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
34. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kid Dis 43 suppl 1 (2004) S1-S290
35. Levey A.S., and Uhlig K. Editorial-Which antihypertensive agents in chronic kidney disease?. Ann Int Med 144 (2006) 213-216
36. Verdecchia P., Reboldi G., Angeli F., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
37. Kostis J.B., Wilson A.C., Freudenberger R.S., Cosgrove N.M., Pressel S.L., and Davis B.R. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 (2005) 29-35
38. Zillich A.J., Garg J., Basu S., Bakris G.L., and Carter B.L. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48 (2006) 219-224
39. Cutler J.A. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key?. Hypertension 48 (2006) 198-200